MedTech News
.................... by Andrew Celentano
Epineuron wins FDA clearance for nerve stimulator
Epineuron announced today that it received FDA 510(k) clearance for its Evala nerve stimulator technology.
First-in-human trial demonstrates promise of implantable cytokine factories for ovarian cancer
Researchers at Rice University, in collaboration with The University of Texas MD Anderson Cancer Center and clinical partners, have reported results from a first-in-human trial evaluating a novel cell-based platform for localized delivery of interleukin-2 (IL-2) in patients with advanced ovarian cancer.
Blood test enables earlier detection of heart and kidney disease
A new way to detect the onset of heart and kidney disease far earlier than previously possible has been discovered by scientists. The breakthrough, published today in Nature Communications, reveals a novel method for identifying damage to the lining of microscopic blood vessels.
AI-powered handheld microscope aims to spot cancer earlier
Researchers at Rice University and The University of Texas MD Anderson Cancer Center have developed a compact, artificial intelligence-powered imaging device that could transform how clinicians detect cancer. The technology, which aims to bring high-resolution, real-time diagnostics directly to the point of care, was recently described in a paper published in the Proceedings of the National Academy of Sciences.
Successfully treated acute myeloid leukemia patients may hold the key to new CAR T cell therapy
Now, a team of researchers from Memorial Sloan Kettering Cancer Center (MSK) has developed a new type of CAR T cell therapy that targets a protein found almost exclusively on leukemia cells and not on healthy cells.
Gene-edited stem cell transplant shows promise for aggressive blood cancers
Researchers at Washington University School of Medicine in St. Louis, showed that a stem cell transplant in which the donor cells have been genetically engineered to remove a particular protein helps prevent toxic side effects and potentially improves the effectiveness of therapies given after a transplant to help prevent cancer recurrence.
Bayesian Health secures first FDA clearance for AI-driven continuous sepsis monitor
The US Food and Drug Administration (FDA) has cleared Bayesian Health’s continuous artificial intelligence (AI)-driven sepsis monitor, making the device the first of its kind to achieve this milestone.
Siemens Healthineers wins FDA clearance for 6 new interventional imaging systems
Siemens Healthineers announced today that the FDA cleared six new systems within its Artis interventional imaging portfolio.